Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023
SKU ID : TNV-13808581 | Publishing Date : 18-Jan-2019 | No. of pages : 118
Detailed TOC of Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Combination therapy - Market size and forecast 2018-2023
• Monotherapy - Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
• Chronic bronchitis
• Emphysema
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• Boehringer Ingelheim
• GlaxoSmithKline
• Novartis
• Teva Pharmaceutical
PART 15: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Years in consideration
Exhibit 02: Global respiratory disorder drugs market
Exhibit 03: Segments of global respiratory disorder drugs market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Pipeline molecules for COPD
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Combination therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Combination therapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Monotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Monotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 25: Sales of monotherapy drugs 2015-2017 ($ millions)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Decision framework
Exhibit 41: Mechanism of action of budesonide/ glycopyrronium/formoterol triple combination
Exhibit 42: New drug approvals for COPD
Exhibit 43: US FDA-approved fixed-dose combination LABAs and LAMAs
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Examples of advanced nebulizers
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: AstraZeneca - Vendor overview
Exhibit 52: AstraZeneca - Business segments
Exhibit 53: AstraZeneca - Organizational developments
Exhibit 54: AstraZeneca - Geographic focus
Exhibit 55: AstraZeneca - Key offerings
Exhibit 56: Boehringer Ingelheim - Vendor overview
Exhibit 57: Boehringer Ingelheim - Business segments
Exhibit 58: Boehringer Ingelheim - Organizational developments
Exhibit 59: Boehringer Ingelheim - Geographic focus
Exhibit 60: Boehringer Ingelheim - Segment focus
Exhibit 61: Boehringer Ingelheim - Key offerings
Exhibit 62: GlaxoSmithKline - Vendor overview
Exhibit 63: GlaxoSmithKline - Business segments
Exhibit 64: GlaxoSmithKline - Organizational developments
Exhibit 65: GlaxoSmithKline - Geographic focus
Exhibit 66: GlaxoSmithKline - Segment focus
Exhibit 67: GlaxoSmithKline - Key offerings
Exhibit 68: Novartis - Vendor overview
Exhibit 69: Novartis - Business segments
Exhibit 70: Novartis - Organizational developments
Exhibit 71: Novartis - Geographic focus
Exhibit 72: Novartis - Segment focus
Exhibit 73: Novartis - Key offerings
Exhibit 74: Teva Pharmaceutical - Vendor overview
Exhibit 75: Teva Pharmaceutical - Business segments
Exhibit 76: Teva Pharmaceutical - Organizational developments
Exhibit 77: Teva Pharmaceutical - Geographic focus
Exhibit 78: Teva Pharmaceutical - Segment focus
Exhibit 79: Teva Pharmaceutical - Key offerings
Exhibit 80: Validation techniques employed for market sizing
Exhibit 81: List of abbreviations
Keyplayers in Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023
AstraZenecaBoehringer Ingelheim
GlaxoSmithKline
Novartis
Teva Pharmaceutical